References
- Ljungman P, Bregni M, Brune M, Cornelissen J, De Witte T, Dini G et
al. Allogeneic and autologous transplantation for haematologic
diseases, solid tumours and immune disorders: current practice in
Europe 2009. Bone Marrow Transplant. 2010;45(2):219-234.
- Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al.
The EBMT activity survey report 2017: a focus on allogeneic HCT for
nonmalignant indications and on the use of non-HCT cell therapies.
Bone Marrow Transplant. 2019;54:1575-1585.
- Gooptu M, Koreth J. Translational and clinical advances in acute
graft-versus-host disease. Haematologica 2020 Nov 1;105(11):2550-2560.
doi:10.3324/haematol.2019.240309.
- MacDonald K, Hill G, Blazer B. Chronic graft-versus-host disease:
biological insights from preclinical and clinical studies. Blood
2017;129:13-21.
- Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al.
Chronic graft-versus-host disease in children: incidence, risk
factors, and impact on outcome. Blood. 2002;100:1192-1200.
- Pulsipher M, Langholz B, Wall D, Schultz K, Bunin N, Carroll W, et al.
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis
in children with ALL: a phase 3 Children’s Oncology/Pediatric Blood
and Marrow Transplant Consortium trial. Blood.2014 Mar
27;123(13):2017-25.
- Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al.
Defining the intensity of conditioning regimens: Working Definitions.
Biol Blood Marrow Transplant 2009; 15:1628-33.
- Przepiorka D, Weisdorf D, Martin R, Klingemann HG, Beatty P, Hows J,
et al. 1994 Consensus conference on Acute GVHD Grading. Bone Marrow
Transplant.1995;15:825-8.
- Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE,
et al. Chronic graft-versus-host syndrome in man. A long-term
clinicopathologic study of 20 Seattle patients. Am J
Med.1980;69:204-17.
- Umeda K, Imai K, Yanagimachi M, Yabe H, Kobayashi M, Takahashi Y, et
al. Impact of graft-versus-host disease on the clinical outcome of
allogeneic hematopoietic stem cell transplantation for non-malignant
diseases. International Journal of Hematology 2020;111:869-876.
- Mahmoud H, Elhaddad A, Fahmy O, Samra M, Abdelfattah R, El-Nahass Y,
et al.
Allogeneic hematopoietic stem cell transplantation for non-malignant
hematological disorders. Journal of Advanced Research. 2015;6:449-438.
- Jacobsohn D, Arora M, Klein J, Hassebroek A, Flowers M, Cutler C et
al. Risk factors associated with increased nonrelapse mortality and
with poor overall survival in children with chronic graft-versus-host
disease. Blood. 2011;118:4472-4479.
- Bertaina M, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et
al. HLA-haploidentical stem cell transplantation after removal of
alphabeta-T and B cells in children with non-malignant disorders.
Blood. 2014;124(5):822-6.
- Zecca M, Strocchio L, Pagliara D, Comoli P, Bertaina A, Giorgiani G,
et al. HLA-haploidentical T-cell depleted allogeneic hematopoietic
stem cell transplantation in children with Fanconi anemia. Biol Blood
Marrow Transplant. 2014;20(4):571-6.
- Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D,
Chuansumrit A, et al. Hematopoietic stem cell transplantation for
homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients
from haploidentical donors. Bone Marrow Transplant. 2016;51(6):813-8.
- Chellapandian D, Sunkersett G, Oshrine B, Galvez Silva J, Ziga E,
Alperstein W, et al. Pediatric HCT in Florida (2014-2016): A Report
from the FPBCC. Pediatric Transplant. 2020 Nov 27;313931. Doi:
10.1111/petr.13931Horan J, Wang T, Haagenson M, Spellman S, Dehn J,
Eapen M, et al. Evaluation of HLA matching in unrelated hematopoietic
stem cell transplantation for non-malignant disorders. Blood.
2012;120:2918-2924.
- Ngwube A, Shah N, Jacobsohn D, Ziga D, Shenoy S. Abatacept is
effective for Gvhd prophylaxis after unrelated donor stem cell
transplantation (URD SCT) for severe sickle cell disease. Blood 2019
134 (Supplement_1:370).
https://doi.org/10.1182/blood-2019-126405.
- Bertaina A, Pitisci A, Sinibaldi M, Algeri M. T Cell-depleted and T
cell-replete HLA-Haploidentical stem cell transplantation for
non-malignant disorders. Curr Hematol Malig Rep. 2017;12:68-78.
- Arcuri L, Nabhan S, Cunha R, Nichele S, Ribeiro A, Fernandes J, et al.
Impact of CD34 cell dose and conditioning regimen on outcomes after
haploidentical donor hematopoietic stem cell transplantation with
post-transplantation cyclophosphamide for relapsed/refractory severe
aplastic anemia. Biol Blood Marrow Transplant. 2020;26:2311-2317.
- Even-Or E, NaserEddin A, Schejter YD, Shadur B, Zaidman I and
Stepensky P. Bone Marrow Transplant. 2020.
https://doi.org/10.1038/s41409-020-01040-9.
- Yu J, Black V, Lamba J, Horn B. Potential risk factors associated with
graft failure of haploidentical hematopoietic stem cell
transplantation (HSCT) in Children with sickle cell disease (SCD). J
Pediatr Hematol Oncol. 2020 Jun 26. doi:10.1097/MPH.0000000000001873.
Figure Legends:
FIGURE 1 Overall survival by acute GVHD grade
FIGURE 2 Overall survival by chronic GVHD grade
Data:
The data that support the findings of this study are available from
the corresponding author upon a reasonable request.
.